Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 27, 2005 Stephen D. Simpson	Will Smith & Nephew Keep Flexing? This smaller, British, orthopedic company has competitive products, but industry trends could hurt it. However, the entire orthopedic sector is getting pretty interesting from a value perspective.
The Motley Fool November 6, 2006 Matthew Crews	Smith & Nephew Is Hip to Growth The medical technology company is showing solid growth, but a possible acquisition is cause for concern. Investors, take note.
The Motley Fool February 9, 2006 Stephen D. Simpson	Growth Not Enough for Smith & Nephew This orthopedic company has market-leading growth, but just not enough cash flow. Investors shouldn't get too excited about these shares.
The Motley Fool December 12, 2006 Matthew Crews	Smith & Nephew, What's the Deal? A merger with Biomet would be good in many ways. But what's the right price? Investors, take note.
The Motley Fool October 5, 2005 Stephen D. Simpson	Wright Goes Wrong A weak third quarter compounds troubles for this pipeline-challenged orthopedics player. There is no compelling reason to purchase this stock today.
The Motley Fool March 22, 2005 Stephen D. Simpson	Can Biomet Elbow the Competition? The No. 4 player in orthopedics looks to close the gap. No matter what valuation metric you want to look at, Biomet shares look expensive on an absolute basis.
The Motley Fool December 21, 2005 Stephen D. Simpson	Biomet Takes a Bum Knee Company excuses aside, a subpar quarter lends credence to the notion that orthopedics companies are still in a tough spot. Investors, take note.
The Motley Fool September 14, 2005 Stephen D. Simpson	Orthopedic Sector Stumbles Already antsy about potential pricing, investors reacted badly to British orthopedic company Smith & Nephew's earnings guidance.
The Motley Fool April 21, 2006 Stephen D. Simpson	Stryker Strikes a Chord A solid quarter and generally positive guidance refuels investor enthusiasm.
The Motley Fool April 13, 2006 Stephen D. Simpson	A Foolish Baby Shower: Stryker Here is a stock you can be comfortable with buying for your little one with the intention that it would be held for at least 18 years.
The Motley Fool July 27, 2006 Stephen D. Simpson	Zimmer Provides Quarterly Information, and More In addition to its quarterly review, the orthopedic company gave some insight into the government probe. Investors, take note.
The Motley Fool April 27, 2006 Stephen D. Simpson	Guidance Brings Zimmer to Its Knees Sales were a little light this quarter, and the company will have to hustle to meet full-year projections. Investors, tread carefully and only buy when there is a fitting margin of safety here.
The Motley Fool July 26, 2007 Ryan Fuhrmann	Zimmer Simmers The maker of hip and knee replacements gets a leg up on the market. Investors, take note.
The Motley Fool January 31, 2006 Stephen D. Simpson	Zimmer Muddles Through So long as the pressures in the orthopedic sector prove less than originally feared, investors could still make money here.
The Motley Fool June 30, 2005 Stephen D. Simpson	Biomet Wants Your Body Steady growth continues at the #4 orthopedics player. But Biomet shares haven't had a great year so far, hovering close to their 52-week low.
The Motley Fool October 25, 2007 Billy Fisher	Plenty of Strength in Zimmer Orthopedic manufacturer Zimmer Holdings reports a solid third quarter, but lowers its forecast for Q4.
The Motley Fool January 29, 2007 Matthew Crews	Only One Bone to Pick With Stryker With products for wherever you hurt, the med-tech company continues to deliver solid earnings.
The Motley Fool July 20, 2007 Ryan Fuhrmann	Stryker Does a Body Good The orthopedics company continues its double-digit growth in an industry with a bright future. Investors, take note.
BusinessWeek November 12, 2007 Arlene Weintraub	Getting Hip to the Boomers Stryker's new orthopedic technology gives aging patients an alternative to full joint replacement.
The Motley Fool January 30, 2007 Ryan Fuhrmann	Zimmer Implants a New High Investors, the orthopedic designer, developer, and manufacturer isn't cheap, but stellar companies rarely are.
The Motley Fool July 21, 2006 Stephen D. Simpson	Stryker and the Terror of the Unknown This has been a pretty bad year to be a good medical technology company. Fears about future pricing and the DOJ investigation keep a lid on the entire sector. So, what about that future for Stryker? Investors, take note.
The Motley Fool October 18, 2007 Billy Fisher	An Empire Strykes Back Stryker reports a quarter of double-digit growth in revenue and earnings. Investors, take note.
The Motley Fool April 26, 2005 Stephen D. Simpson	Growth Is Knee-High Zimmer turns in another fine quarter, with strength in knee implants leading the way.
The Motley Fool September 20, 2006 Ryan Fuhrmann	Biomet's Aching Joints Biomet operates in the appealing medical device industry, but current growth trends are giving investors a headache.
The Motley Fool January 27, 2006 Stephen D. Simpson	Lightning Stryker The dust hasn't yet settled on the orthopedic sector, so wise investors should tread lightly with this medical technology company.
The Motley Fool March 31, 2005 Stephen D. Simpson	The DOJ Goes Fishing for Orthopedics The government's industry-wide investigation of orthopedics is more of a buying opportunity than a real threat.
The Motley Fool August 28, 2008 Brian Orelli	Stryker Strikes Back The orthopedics maker sues to stop a costly federal investigation.
The Motley Fool April 27, 2007 Ryan Fuhrmann	Hip Results at Zimmer Holdings The orthopedic-implant and surgical-product maker is impressing investors, and it may just be warming up.
The Motley Fool October 17, 2008 Brian Orelli	Shareholders Slap Stryker A little earnings miss sends the medical technology company down more than necessary.
The Motley Fool February 1, 2005 Stephen D. Simpson	Zimmer Shoots From the Hip Pure-play orthopedic company delivers the goods, but at what cost? Zimmer carries a price tag that would make a value investor's bones ache.
The Motley Fool September 21, 2005 Stephen D. Simpson	Can Biomet Stay Limber? Concerns about pricing have buffeted the orthopedic space and the No. 4 player in hips and knees. Whatever the case turns out to be, Biomet is probably a bit riskier than average.
The Motley Fool April 28, 2004 Glen Trematore	Zimmer Makes a Family Proud Zimmer Holdings looks strong when compared with other orthopedic/medical device makers.
The Motley Fool July 23, 2010 Jordan DiPietro	Better Health Care Buy: Stryker or Zimmer Holdings? Which stock is a better purchase to consider?
The Motley Fool July 18, 2008 Brian Orelli	What Strikes Against Stryker? High growth isn't enough to impress investors.
The Motley Fool March 21, 2006 Stephen D. Simpson	Biomet's Stiff Joints Pricing isn't collapsing, but the orthopedics company isn't exactly prospering, either. Investors, beware.
The Motley Fool November 6, 2006	Merger Ahead for Smith & Nephew?: Fool by Numbers The medical technology company released third-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
The Motley Fool June 28, 2006 Stephen D. Simpson	Feds Once Again Knocking on Ortho Doors A second round of subpoenas rattles the medical device sector.
The Motley Fool October 19, 2005 Stephen D. Simpson	Stryker Still on Target The ever-present 20% growth target will get tougher to hit, but this is a quality medical company. Investors, take note.
CRM February 2004 Lisa Picarille	Mobile CRM Helps Smith & Nephew Reps Customized applications allow sales reps to have all the resources, technical knowledge, and credibility of their product development department.
The Motley Fool July 28, 2005 Stephen D. Simpson	Zimmer at a Simmer Strong demand for reconstructive products keeps this orthopedics company limber. Zimmer's 30-plus trailing price-to-earnings ratio still looks high, but it is in line with this industry's current multiples.
The Motley Fool January 28, 2011 Michael Olsen	Rising Star Buy: Zimmer Holdings Current trends, coupled with an aging population, should provide consistent and growing demand for Zimmer's wares.
The Motley Fool January 4, 2011 Seth Jayson	Here's How Smith & Nephew Is Making You So Much Cash With questionable cash flows amounting to only 8.1% of operating cash flow, Smith & Nephew's cash flows look clean.
The Motley Fool January 27, 2006 Rich Smith	Foolish Forecast: Boning Up on Zimmer With its margins as high as they are, and rising as steadily as they are, you won't be surprised to hear that the medical technology company's shares command premium prices.
BusinessWeek December 3, 2007 Arlene Weintraub	Is the Hip Bone Connected To a Fee? An investigation alleges some orthopedics makers have showered surgeons with fees and perks.
Entrepreneur August 2003 Devlin Smith	Worth His Weight With a growing chain of weight-loss center locations, this franchisee proves he's got what it takes to succeed.
The Motley Fool September 27, 2005 Stephen D. Simpson	Not Bracing for the Worst Price competition and tighter reimbursement? dj Orthopedics isn't worrying about them. Investors may not rush to sell, but they should perhaps start thinking about a protective stop-loss to lock on some easy profits.
The Motley Fool December 27, 2005 Jack Uldrich	Nucryst's Nano IPO Could Burn Investors Investors in this pharmaceutical should proceed with great caution because they risk getting burned from this IPO.
The Motley Fool February 6, 2004	Smith Holds Martha, Sells Atkins Starbucks CEO Orin Smith talks about the prospects of talked-about stocks.
The Motley Fool January 28, 2009 Brian Orelli	The Streak Is Over After 31 consecutive quarters of double-digit sales growth, medical device maker Stryker finally had an off quarter.
Registered Rep. December 1, 2005 Halah Touryalai	Smith Barney: New Focus On the Horizon While most Smith Barney advisor respondents were generally unimpressed by the acquisition of Legg advisors, it'll be interesting to see if Smith Barney's jettisoning of its asset management group -- and resulting new focus on retail distribution -- will rejuvenate the firm.